<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04910477</url>
  </required_header>
  <id_info>
    <org_study_id>17300608</org_study_id>
    <nct_id>NCT04910477</nct_id>
  </id_info>
  <brief_title>Nebulized Dexmedetomidine Versus Neostigmine/Atropine in Postdural Puncture Headache</brief_title>
  <official_title>Comparative Effects of Nebulized Dexmedetomidine Versus Neostigmine / Atropine in Treating Postdural Puncture Headache After Cesarean Section: A Double Blind Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In our study, we will compare a new route of nebulization for effectiveness between&#xD;
      dexmedetomidine, neostigmine/atropine and saline placebo for females complained of postdural&#xD;
      puncture headache (PDPH) after cesarean section.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A written informed consent will be taken from the patients. The study will involve female&#xD;
      adults (age 18-40years) of American society of anesthesiologists (ASA) I-II who are listed&#xD;
      for elective cesarean section under spinal anesthesia and suffer from postoperative postdural&#xD;
      puncture headache (PDPH). Patients will be assigned randomly to three groups (30 subjects&#xD;
      each) after PDPH diagnosis was established. First 90 patients developed PDPH will be assessed&#xD;
      for study eligibility.&#xD;
&#xD;
      Group D (patients will receive ultrasonic nebulization of dexmedetomidine (1 mg/kg diluted in&#xD;
      4 mL saline) twice daily for three days. Group N (patients will receive nebulization of 20&#xD;
      µ/kg neostigmine and 10 µ/kg atropine mixed in 4 ml) twice daily for three days. Group S&#xD;
      (patients will receive nebulization of saline placebo in 4 ml) twice daily for three days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Actual">September 3, 2021</completion_date>
  <primary_completion_date type="Actual">September 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>visual analog scale score (VAS) ≤3 within 72 hour.</measure>
    <time_frame>3 days</time_frame>
    <description>change in visual analog scale score (VAS )for the assessment of the degree of headache (with 0 representing no headache and 10 cm representing the worst imaginable headache). a visual analog scale score ≤3 within 72 hour after intervention will be recorded.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Need for Epidural blood patch</measure>
    <time_frame>Day 4</time_frame>
    <description>Epidural blood patch will be done in failed study drugs, traditional treatment and taking consent from patients after 72h from intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurence of neck stiffness</measure>
    <time_frame>3 days</time_frame>
    <description>If there is occurance of neck stiffness after start of PDPH</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Postdural Puncture Headache</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group D (patients will receive ultrasonic nebulization of dexmedetomidine (1 mg/kg diluted in 4 mL saline) twice daily for three days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neostigmine/atropine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group N (patients will receive nebulization of 20 µ/kg neostigmine and 10 µ/kg atropine mixed in 4 ml) twice daily for three days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group S (patients will receive nebulization of saline placebo in 4 ml)twice daily for three days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>ultrasonic nebulization of dexmedetomidine (1 mg/kg diluted in 4 mL saline) twice daily for three days.</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neostigmine/atropine</intervention_name>
    <description>nebulization of 20 µ/kg neostigmine and 10 µ/kg atropine mixed in 4 ml) twice daily for three days.</description>
    <arm_group_label>Neostigmine/atropine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline placebo</intervention_name>
    <description>nebulization of saline placebo in 4 ml) twice daily for three days.</description>
    <arm_group_label>Saline placebo</arm_group_label>
    <other_name>Normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Clinical diagnosis of postdural puncture headache (PDPH) after elective cesarean section&#xD;
        under spinal anesthesia.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypersensitivity of dexmedetomidine, neostigmine or atropine&#xD;
&#xD;
          -  Overactive thyroid gland&#xD;
&#xD;
          -  Myasthenia gravis&#xD;
&#xD;
          -  Closed angle glaucoma&#xD;
&#xD;
          -  High blood pressure and coronary artery disease.&#xD;
&#xD;
          -  withdrawal of consent&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female suffering from PDPH after cesarean section</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Omar Soliman</last_name>
    <role>Principal Investigator</role>
    <affiliation>Omar makram</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Assiut university hospital</name>
      <address>
        <city>Assiut</city>
        <zip>Assuit universi</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 25, 2021</study_first_submitted>
  <study_first_submitted_qc>May 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 2, 2021</study_first_posted>
  <last_update_submitted>September 5, 2021</last_update_submitted>
  <last_update_submitted_qc>September 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Omar Makram Soliman</investigator_full_name>
    <investigator_title>Lecturer of anesthesia and ICU</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Post-Dural Puncture Headache</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atropine</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Neostigmine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

